Drug discovery

Lucy Therapeutics Expands Leadership Team with Appointment of Julia Gaebler, Ph.D., as Chief Business Officer

Retrieved on: 
Tuesday, November 15, 2022

Lucy Therapeutics, Inc., a private biotech company developing proprietary mitochondrial-based small molecule therapies and biomarkers for neurological diseases, today announced the appointment of business-side biopharma leader Julia Gaebler, Ph.D., as Chief Business Officer.

Key Points: 
  • Lucy Therapeutics, Inc., a private biotech company developing proprietary mitochondrial-based small molecule therapies and biomarkers for neurological diseases, today announced the appointment of business-side biopharma leader Julia Gaebler, Ph.D., as Chief Business Officer.
  • Dr. Gaebler has more than 25 years of business development and strategy experience in the life sciences industry, across biopharma, consulting, and academia.
  • View the full release here: https://www.businesswire.com/news/home/20221115005644/en/
    Dr. Gaebler will direct Lucy Therapeutics fundraising, growth and partnership activities for its promising proprietary preclinical compounds in Parkinsons disease, Rett syndrome, and other diseases of mitochondrial dysfunction.
  • Prior to joining Lucy Therapeutics, Dr. Gaebler was vice president of commercial strategy and portfolio planning at Milestone Pharmaceuticals and partner at Health Advances, a life-sciences strategy consulting firm.

Casma Therapeutics Raises $46.0 M in Series C Funding

Retrieved on: 
Tuesday, November 15, 2022

Casma Therapeutics , Inc., a biotechnology company engaging the autophagy system to provide innovative new medicines, today announced the closing of a Series C financing round of $46.0 million.

Key Points: 
  • Casma Therapeutics , Inc., a biotechnology company engaging the autophagy system to provide innovative new medicines, today announced the closing of a Series C financing round of $46.0 million.
  • Current investors Eventide Asset Management, LLC, Schroders Capital, The Column Group, Third Rock Ventures, and other funds also participated in the financing.
  • Casma will use proceeds to advance its lead program for MYD88 mutant lymphoma through preclinical and into IND enabling studies.
  • We expect that this round of funding will accelerate development of Casmas pipeline assets, especially its degrader for MYD88 mutant tumors.

LabGenius Appoints Dr. Leonard Wossnig as Chief Technology Officer

Retrieved on: 
Wednesday, November 16, 2022

LabGenius, a pioneer in the use of machine learning (ML) for antibody-based drug discovery, today announced the appointment of Leonard Wossnig Ph.D. as Chief Technology Officer (CTO).

Key Points: 
  • LabGenius, a pioneer in the use of machine learning (ML) for antibody-based drug discovery, today announced the appointment of Leonard Wossnig Ph.D. as Chief Technology Officer (CTO).
  • In this role, Leonard will lead a team of Data Scientists, Software Engineers, and Automation Experts to further enhance LabGenius data-driven platform capabilities.
  • View the full release here: https://www.businesswire.com/news/home/20221115005063/en/
    Leonard is a brilliant addition to our team, says LabGenius CEO and Founder, Dr. James Field.
  • In 2018, Leonard co-founded Rahko, a leading quantum machine learning company whose technology platform combined computational chemistry, machine learning and quantum computing to drive a better understanding of drug behaviour.

Cybin Inc. Presents CYB003 Preclinical Data at Neuroscience 2022

Retrieved on: 
Tuesday, November 15, 2022

Cybin Inc. (NEO:CYBN) (NYSE American: CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics, today announced that the Company presented a poster highlighting preclinical data for its deuterated psilocybin analog, CYB003 at Neuroscience 2022 hosted by the Society for Neuroscience (SFN) taking place November 12-16, 2022, in San Diego, CA.

Key Points: 
  • Cybin Inc. (NEO:CYBN) (NYSE American: CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics, today announced that the Company presented a poster highlighting preclinical data for its deuterated psilocybin analog, CYB003 at Neuroscience 2022 hosted by the Society for Neuroscience (SFN) taking place November 12-16, 2022, in San Diego, CA.
  • Our presentation at Neuroscience 2022 highlighted the findings from our CYB003 preclinical studies.
  • Compared to classical psilocybin, CYB003 has demonstrated less variability in plasma levels, faster onset of action, and shorter duration of effect.
  • CYB003 is currently being evaluated in a Phase 1/2a clinical trial for the treatment of major depressive disorder.

Cybin Inc. Reports Second Quarter Financial Results and Recent Business Highlights

Retrieved on: 
Monday, November 14, 2022

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics, today reported unaudited financial results for its second quarter ended September 30, 2022, and recent business highlights.

Key Points: 
  • Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics, today reported unaudited financial results for its second quarter ended September 30, 2022, and recent business highlights.
  • Depending on market conditions, this will allow Cybin to access additional cash for growth opportunities and working capital.
  • Recent Business and Pipeline Highlights:
    Reported progress update on CYB004-E Phase 1 trial.
  • Collectively, Cybin now has access to more than 35 patents and applications through a combination of internal filings and licensing arrangements.

Worldwide Cheminformatics Industry to 2027 - by Application, End-user and Region - ResearchAndMarkets.com

Retrieved on: 
Monday, November 14, 2022

The "Global Cheminformatics Market by Application, End-user, Company, and Region: Competition Forecast and Opportunities to 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Cheminformatics Market by Application, End-user, Company, and Region: Competition Forecast and Opportunities to 2027" report has been added to ResearchAndMarkets.com's offering.
  • The major factors like increasing awareness of personalized medicine combined with unsustainable liability of chronic disease are propelling the growth of global cheminformatics market.
  • Moreover, due to the awareness of personalized drugs among people, a sudden increase in usage of stratified medicines has made a positive influence on the cheminformatics market.
  • The increased awareness regarding the personalized medicines and surge in chronic diseases is driving the Cheminformatics market growth, globally.

Synthetic Biology Global Market Report 2022: Demand For Biofuel Presents Lucrative Opportunities - ResearchAndMarkets.com

Retrieved on: 
Monday, November 14, 2022

The global synthetic biology market size is expected to reach USD 55,371.1 million by 2030, registering a CAGR of 19.7% during the forecast period, according to this report.

Key Points: 
  • The global synthetic biology market size is expected to reach USD 55,371.1 million by 2030, registering a CAGR of 19.7% during the forecast period, according to this report.
  • Furthermore, support from government agencies and the presence of several programs are likely to boost the market growth.
  • Other factors such as expanding demand in industries such as textiles and nutrition are also contributing to the market growth.
  • In addition, synthetic biology is predicted to aid in the generation of higher agricultural yields and pest control development.

Alice Zhang, CEO & Co-founder of Verge Genomics, Recognized Today by Both Fortune and Fierce Biotech as a Pioneer in AI-Driven Drug Discovery

Retrieved on: 
Monday, November 14, 2022

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20221114005218/en/
    The biotech startup phenotype is changing and so are its leaders, said Alice Zhang, CEO of Verge Genomics.
  • Fortune annually names 40 men and women under the age of 40 who are influential leaders in their industry.
  • As a co-founder and CEO, Zhang leads a team of scientists and engineers using technology to transform the drug discovery process.
  • Verge has built CONVERGE, an end-to-end drug discovery and development platform, that integrates multiple technological innovations from discovery to translation to streamline drug development.

Exscientia and MD Anderson Launch Strategic Collaboration to Leverage AI in Developing Novel Oncology Treatments

Retrieved on: 
Monday, November 14, 2022

Exscientia plc (Nasdaq: EXAI) and The University of Texas MD Anderson Cancer Center today announced a strategic collaboration to align the patient-centric artificial intelligence (AI) capabilities of Exscientia with the drug discovery and development expertise of MD Anderson in order to advance novel small-molecule oncology therapies.

Key Points: 
  • Exscientia plc (Nasdaq: EXAI) and The University of Texas MD Anderson Cancer Center today announced a strategic collaboration to align the patient-centric artificial intelligence (AI) capabilities of Exscientia with the drug discovery and development expertise of MD Anderson in order to advance novel small-molecule oncology therapies.
  • Exscientia will collaborate with the team at IACS, a drug discovery engine focused on developing novel small-molecule therapeutics.
  • We are tremendously proud to work alongside MD Anderson to harness our AI-driven platform toward the discovery of next-generation cancer treatments.
  • Under the agreement terms, Exscientia and MD Anderson will jointly contribute to and support each program designated to move forward.

Enanta Pharmaceuticals to Host Conference Call on November 21 at 4:30 p.m. ET to Discuss its Financial Results for Its Fiscal Fourth Quarter and Full Year Ended September 30, 2022

Retrieved on: 
Monday, November 14, 2022

Enanta management will then host a conference call at 4:30 p.m.

Key Points: 
  • Enanta management will then host a conference call at 4:30 p.m.
  • ET to discuss these results and provide an update on Enantas business, including its research and development pipeline.
  • The live webcast can be accessed under "Events & Presentations" in the investors section of Enantas website https://ir.enanta.com/events-presentations or by clicking here .
  • It is recommended that participants register a day in advance or at a minimum of 15 minutes before the call.